J Breast Cancer.
2020 Apr;23(2):129-140. 10.4048/jbc.2020.23.e10.
The Role of Long Noncoding RNAs in Antiestrogen Resistance in Breast Cancer: An Overview and Update
- Affiliations
-
- 1Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, China
- 2Institute of Cancer Prevention and Treatment, Harbin Medical University, Harbin, China
- 3Heilongjiang Academy of Medical Sciences, Harbin, China
- KMID: 2500150
- DOI: http://doi.org/10.4048/jbc.2020.23.e10
Abstract
- As a standard treatment, endocrine therapy has dramatically enhanced the prognosis of patients with estrogen receptor (ER)-positive breast cancer, which accounts for nearly 70% of all breast cancers. Antiestrogen drugs such as tamoxifen and aromatase inhibitors are the standard treatment options for ERα-positive breast cancer. However, acquired antiestrogen resistance is still the leading cause of disease recurrence and progression. Evidence has shown that long noncoding RNAs (lncRNAs) play an essential role in the development of antiestrogen resistance in ER-positive breast cancer and can serve as biomarkers or potential therapeutic targets. This review highlights the role of lncRNAs in the development of antiestrogen resistance in breast cancer.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Regulation Mechanism of Long Noncoding RNAs in Colon Cancer Development and Progression
- Role of Long Non-coding Ribonucleic Acid in Gastrointestinal Cancer
- MiR-4492, a New Potential MicroRNA for Cancer Diagnosis and Treatment: A Mini Review
- Roles of Oncogenic Long Non-coding RNAs in Cancer Development
- Potential Implications of Long Noncoding RNAs in Autoimmune Diseases
